Alendronate

Absorption	Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.
Volume of distribution	28 L
Protein binding	78%
Metabolism	There is no evidence that alendronate is metabolized in humans or animals.
Route of elimination	Following a single IV dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces.
Half life	>10 years
Clearance	<200 mL/min [A single 10 mg IV dose]
Toxicity	Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."
Affected organisms	Humans and other mammals
Pathways	Pathway Name SMPDB ID Alendronate pathway